IL232648B - An isolated peptide to inhibit gm–csf activity - Google Patents

An isolated peptide to inhibit gm–csf activity

Info

Publication number
IL232648B
IL232648B IL232648A IL23264814A IL232648B IL 232648 B IL232648 B IL 232648B IL 232648 A IL232648 A IL 232648A IL 23264814 A IL23264814 A IL 23264814A IL 232648 B IL232648 B IL 232648B
Authority
IL
Israel
Prior art keywords
inhibiting
isolated peptide
csf activity
csf
activity
Prior art date
Application number
IL232648A
Other languages
English (en)
Hebrew (he)
Other versions
IL232648A0 (en
Inventor
Bozena Kaminska-Kaczmarek
Malgorzata Sielska
Aleksandra Ellert-Miklaszewska
Pawel Wisniewski
Original Assignee
Nencki Inst Of Experimental Biology
Glia Sp Z O O
Kaminska Kaczmarek Bozena
Malgorzata Sielska
Ellert Miklaszewska Aleksandra
Pawel Wisniewski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nencki Inst Of Experimental Biology, Glia Sp Z O O, Kaminska Kaczmarek Bozena, Malgorzata Sielska, Ellert Miklaszewska Aleksandra, Pawel Wisniewski filed Critical Nencki Inst Of Experimental Biology
Publication of IL232648A0 publication Critical patent/IL232648A0/en
Publication of IL232648B publication Critical patent/IL232648B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL232648A 2011-11-17 2014-05-15 An isolated peptide to inhibit gm–csf activity IL232648B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161561080P 2011-11-17 2011-11-17
US201261583745P 2012-01-06 2012-01-06
PCT/IB2012/056533 WO2013072901A2 (en) 2011-11-17 2012-11-18 Compositions and methods for treating glioma

Publications (2)

Publication Number Publication Date
IL232648A0 IL232648A0 (en) 2014-06-30
IL232648B true IL232648B (en) 2021-12-01

Family

ID=47358252

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232648A IL232648B (en) 2011-11-17 2014-05-15 An isolated peptide to inhibit gm–csf activity

Country Status (7)

Country Link
US (2) US9453050B2 (https=)
EP (1) EP2780363B1 (https=)
JP (1) JP6426001B2 (https=)
KR (1) KR20140103122A (https=)
CA (1) CA2856329A1 (https=)
IL (1) IL232648B (https=)
WO (1) WO2013072901A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
SG11201702475VA (en) * 2014-09-26 2017-04-27 Univ Singapore Methods and compositions for modulating th-gm cell function
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020110117A1 (en) * 2018-11-28 2020-06-04 Glia Sp. Z O.O. Compositions and methods for treating glioma
CN112007142B (zh) * 2019-05-31 2025-04-22 生物蚕茧研究所股份有限公司 向抗炎m2表型小胶质细胞的极性转化促进剂
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102899196B1 (ko) * 2023-01-20 2025-12-12 (주) 넥셀 치주염 및 임플란트 주변염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 치주염 및 임플란트 주변염 예방 또는 치료용 조성물
CN116650650A (zh) * 2023-06-12 2023-08-29 郑州大学 一种抑制食管鳞癌中肿瘤相关巨噬细胞浸润的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
AU630496B2 (en) * 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
WO1991002063A1 (en) * 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
CA2288680A1 (en) 1998-11-12 2000-05-12 Jcr Pharmaceuticals Co., Ltd. Modulation of cell proliferative disorders by cyclic rgd
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
BR9916536A (pt) 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US6521593B1 (en) 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
WO2001074855A2 (en) * 2000-03-30 2001-10-11 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2004018498A2 (en) * 2002-05-10 2004-03-04 Children's Medical Center Corporation Minicell display and products therefrom
WO2006087579A1 (en) * 2005-02-18 2006-08-24 Proximagen Ltd. Treatment for neurodegeneration
EP2377884A1 (en) * 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
WO2007035843A2 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
PL1999152T3 (pl) * 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
DK2121586T3 (en) 2007-03-09 2017-06-19 Pathologica Llc MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS
ES2538362T3 (es) 2007-10-16 2015-06-19 Ventana Medical Systems, Inc. Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN102223915A (zh) 2008-11-20 2011-10-19 默克专利有限公司 应用整联蛋白配体治疗癌症的新疗法和药物
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
BR112012027745A2 (pt) * 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia

Also Published As

Publication number Publication date
CA2856329A1 (en) 2013-05-23
EP2780363A2 (en) 2014-09-24
KR20140103122A (ko) 2014-08-25
US20140256628A1 (en) 2014-09-11
US20170035851A1 (en) 2017-02-09
EP2780363B1 (en) 2019-07-03
JP6426001B2 (ja) 2018-11-21
JP2014533681A (ja) 2014-12-15
WO2013072901A2 (en) 2013-05-23
WO2013072901A3 (en) 2013-07-25
US9453050B2 (en) 2016-09-27
IL232648A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
GB2491912B (en) Terminal location
TWI561211B (en) Image-processor-controlled misalignment-reduction for ophthalmic systems
ZA201402164B (en) Protein kinase inhibitors
GB201105902D0 (en) Location system
IL232648B (en) An isolated peptide to inhibit gm–csf activity
ZA201306855B (en) Protein kinase inhibitors
EP2673635A4 (en) IMMUNOTHERAPY THROUGH APOE
PL2699674T3 (pl) Syntetyczne warianty fitazy
GB201111183D0 (en) Peptide
GB201115910D0 (en) Peptides
GB201301300D0 (en) No details
GB201102347D0 (en) Positioning system
EP2671008A4 (en) VALVE SYSTEM
IL228650A0 (en) pepper rhizome
IL232848A0 (en) Human gene derived promoter
GB201107468D0 (en) Protein expression systems
ZA201306415B (en) Peptide deformylase inhibitors
ZA201404044B (en) Peptide deformylase inhibitors
GB201103407D0 (en) Genetic association
GB201115014D0 (en) Peptides
GB201112985D0 (en) Polypeptide
GB201112849D0 (en) Polypeptide
GB201106130D0 (en) Polypeptide
GB201115923D0 (en) High grain technology
AU339832S (en) Dish